This document provides a summary of the history and growth of Sun Pharmaceutical Industries Ltd., one of the largest pharmaceutical companies in the world. It was founded in 1983 in India by Dilip Shanghvi and started with 5 psychiatry products. Over the decades, it has expanded significantly through acquisitions and new facilities, becoming a global leader in generic and branded generics drugs with a presence worldwide. Key acquisitions and events that fueled its growth include Ranbaxy in 2014, Caraco Pharmaceutical in 2004, and other companies, expanding its product portfolio and global reach.
Ranbaxy Laboratories is an international pharmaceutical company headquartered in India. It manufactures generic and branded generic drugs and has manufacturing facilities in several countries. The document discusses Ranbaxy's business overview, financial performance from 2004-2008, demand forecasting for 2010, and recommendations. Ranbaxy's sales grew from 2004-2008 but it reported a net loss in 2008 due to issues with the US FDA and forex losses. Demand forecasting using a linear trend line model estimates Ranbaxy's sales in 2010 will be approximately Rs. 47,315.20 crores.
Ranbaxy Laboratories was founded in 1937 in India and became a public company in 1973. It was acquired by Daiichi Sankyo in 2008. Whistleblowers in 2004 revealed that Ranbaxy had fabricated drug test reports, resulting in warnings from the FDA and import bans. Ranbaxy pleaded guilty in 2013 to drug safety violations and paid $500 million in fines. Several plants including Toansa were banned by the FDA for quality control issues such as contaminated products, poor facilities, and inaccurate data. The culture change needed to resolve Ranbaxy's problems fully will take strong leadership over the long term.
Ranbaxy Laboratories Limited is India's largest pharmaceutical company with a presence in 43 countries and manufacturing facilities in 8 countries. It produces affordable generic medicines and serves over 125 countries. In 2008, it entered an alliance with Daiichi Sankyo to create an innovator and generic pharmaceutical powerhouse, ranking among the top 20 global pharmaceutical companies. For 2011, it recorded global sales of $2.1 billion from both emerging and developed markets. It focuses on increasing generics business through organic and inorganic growth across geographies.
The document is an industrial training report submitted by Jayesh Mohansing Rajput to fulfill requirements for a Bachelor of Pharmacy degree. It provides an overview of his training at Glenmark Pharmaceuticals Ltd in Nashik, India. The report describes Glenmark's history and facilities, including departments for documentation, production, quality control, and quality assurance. It also lists some of Glenmark's regulatory approvals and top-selling products.
Zydus Group was founded in 1952 and restructured in 1995 into Cadila Healthcare and Cadila Pharmaceuticals. Cadila Healthcare later adopted the name Zydus Group. Zydus Group has achieved strong growth in global markets like the US, Europe, Japan, and emerging markets. In the US, Zydus is among the top 20 fastest growing generic companies and focuses on difficult to make products. Financially, Zydus has grown significantly from 2005-2006 to 2009-2010 in total income, EBIT, EPS, and R&D expenditures.
This document provides biographical and professional details about Ram Gulwady in 3 pages. It includes his name, date of birth, current position as Managing Director of Sanmour Pharma, educational qualifications, over 30 years of professional experience in various roles in pharmaceutical companies in India and abroad, areas of technical expertise, and a list of clients. The document highlights Gulwady's leadership experience in setting up R&D labs, manufacturing plants, and transferring technology internationally.
This is the report of my first Summer training in BBA at Lupin, Ankleshwar plant. This whole report is prepared by me with the help of information provided by the company. Production, Dispatch, Store-warehouse, Purchase, Financial, HR departments are included in this project.
This project also include a Mini Project on "Job Satisfaction". I complete this project with the help of Random Survey method. I hop this report will help you in your study.
For any kind of query or correction in the project contact me through
email- rajat.gandhi27@gmail.com
facebook- www.facebook.com/rajat.gandhi28
Ranbaxy Laboratories is an international pharmaceutical company headquartered in India. It manufactures generic and branded generic drugs and has manufacturing facilities in several countries. The document discusses Ranbaxy's business overview, financial performance from 2004-2008, demand forecasting for 2010, and recommendations. Ranbaxy's sales grew from 2004-2008 but it reported a net loss in 2008 due to issues with the US FDA and forex losses. Demand forecasting using a linear trend line model estimates Ranbaxy's sales in 2010 will be approximately Rs. 47,315.20 crores.
Ranbaxy Laboratories was founded in 1937 in India and became a public company in 1973. It was acquired by Daiichi Sankyo in 2008. Whistleblowers in 2004 revealed that Ranbaxy had fabricated drug test reports, resulting in warnings from the FDA and import bans. Ranbaxy pleaded guilty in 2013 to drug safety violations and paid $500 million in fines. Several plants including Toansa were banned by the FDA for quality control issues such as contaminated products, poor facilities, and inaccurate data. The culture change needed to resolve Ranbaxy's problems fully will take strong leadership over the long term.
Ranbaxy Laboratories Limited is India's largest pharmaceutical company with a presence in 43 countries and manufacturing facilities in 8 countries. It produces affordable generic medicines and serves over 125 countries. In 2008, it entered an alliance with Daiichi Sankyo to create an innovator and generic pharmaceutical powerhouse, ranking among the top 20 global pharmaceutical companies. For 2011, it recorded global sales of $2.1 billion from both emerging and developed markets. It focuses on increasing generics business through organic and inorganic growth across geographies.
The document is an industrial training report submitted by Jayesh Mohansing Rajput to fulfill requirements for a Bachelor of Pharmacy degree. It provides an overview of his training at Glenmark Pharmaceuticals Ltd in Nashik, India. The report describes Glenmark's history and facilities, including departments for documentation, production, quality control, and quality assurance. It also lists some of Glenmark's regulatory approvals and top-selling products.
Zydus Group was founded in 1952 and restructured in 1995 into Cadila Healthcare and Cadila Pharmaceuticals. Cadila Healthcare later adopted the name Zydus Group. Zydus Group has achieved strong growth in global markets like the US, Europe, Japan, and emerging markets. In the US, Zydus is among the top 20 fastest growing generic companies and focuses on difficult to make products. Financially, Zydus has grown significantly from 2005-2006 to 2009-2010 in total income, EBIT, EPS, and R&D expenditures.
This document provides biographical and professional details about Ram Gulwady in 3 pages. It includes his name, date of birth, current position as Managing Director of Sanmour Pharma, educational qualifications, over 30 years of professional experience in various roles in pharmaceutical companies in India and abroad, areas of technical expertise, and a list of clients. The document highlights Gulwady's leadership experience in setting up R&D labs, manufacturing plants, and transferring technology internationally.
This is the report of my first Summer training in BBA at Lupin, Ankleshwar plant. This whole report is prepared by me with the help of information provided by the company. Production, Dispatch, Store-warehouse, Purchase, Financial, HR departments are included in this project.
This project also include a Mini Project on "Job Satisfaction". I complete this project with the help of Random Survey method. I hop this report will help you in your study.
For any kind of query or correction in the project contact me through
email- rajat.gandhi27@gmail.com
facebook- www.facebook.com/rajat.gandhi28
This document provides information about Ranbaxy Laboratories Limited, including its group members, industry profile, company profile, vision, mission, and key areas like marketing, HR, finance, and recent news. It discusses that Ranbaxy is India's largest pharmaceutical company, ranked 8th globally in generics. It has manufacturing in 11 countries and a presence in 49 countries. The company aims to achieve customer satisfaction and be a responsible corporate citizen.
Sun Pharmaceuticals was founded in 1983 and has since grown to be one of the largest pharmaceutical companies globally through strategic mergers and acquisitions. Some of its most significant acquisitions include Ranbaxy Laboratories in 2014, which made it the largest pharmaceutical company in India. Sun Pharma focuses on generic and specialty drugs and generates most of its revenue from sales in the United States. It employs over 32,000 people worldwide and achieved $166 billion in revenue in 2013-2014 through its global manufacturing and distribution network. The company's leadership emphasizes the importance of speed, perfection, and building a strong team to drive continued growth.
Aurobindo Pharma Ltd. is an Indian pharmaceutical company established in 1986 that focuses on formulations. It has a vertically integrated business with in-house R&D and manufacturing approved by major global regulatory bodies. Aurobindo exports medications to over 125 countries, with international operations accounting for over 70% of its revenues. It has over 7,800 employees including 700 scientists and facilities across 5 million square meters.
Group No. 4 set a vision in 2007 to achieve $1 billion in sales, dubbed the "Healthy Billion." In fiscal year 2010-2011, they crossed the $1 billion mark, achieving their goal. They now aspire to reach $3 billion in sales by 2015. The company maintained strong growth across its business segments including India formulations, international formulations, API and intermediates, animal health, and wellness. New product launches and geographic expansions contributed to the financial success.
Fundamental Analysis of Aurobindo Pharma StockAshish Sharma
The document analyzes the financial performance of Aurobindo Pharma, an Indian pharmaceutical company founded in 1986. It provides financial ratios for Aurobindo compared to industry averages from 2010-2014, showing that Aurobindo generally performs better than average across current ratio, quick ratio, debt-equity ratio, interest coverage ratio, debtors turnover ratio, creditors turnover ratio, stock turnover ratio, gross profit ratio, net profit ratio, return on assets, return on capital employed, price-earnings ratio, earnings per share, book value per share, dividend per share and dividend yield ratio. The document also lists cash flow figures for Aurobindo from 2009-2013.
Pankaj Patel holds degrees in pharmacy and pursued further studies in pharmaceutical technology. He is the Chairman and Managing Director of Cadila Healthcare Limited and its subsidiary Zydus Animal Health Limited. He has led the company's acquisitions, received several honors, and helped develop an H1N1 vaccine. His career has been defined by great leadership, visionary strategy, determination, innovation, and a simple approach.
Ranbaxy is India's largest pharmaceutical company with a global footprint in 43 countries. It has a diverse product portfolio and strong R&D capabilities. In 2011, Ranbaxy recorded global sales of $2.1 billion, with emerging and developed markets each contributing around 47% and 46% respectively. Ranbaxy aims to grow organically and inorganically, focusing on high-growth areas like biologics and injectables. It also has a hybrid business model through its alliance with Daiichi Sankyo to create an innovator and generic powerhouse. Ranbaxy emphasizes R&D as a strategic priority and has over 1,200 personnel dedicated to research.
Dilip Shanghvi is the founder and managing director of Sun Pharmaceuticals, which he started in 1982 with Rs. 10,000 capital. Under his leadership, Sun Pharmaceuticals has grown to become India's largest drugmaker and most valuable pharmaceutical company. Shanghvi launched his career helping his father's wholesale drugs business and realized he could manufacture his own drugs. Through strategic acquisitions over the decades, Sun Pharmaceuticals now has a global presence and Shanghvi has a net worth of over $18 billion, making him one of Asia's richest self-made billionaires.
Dilip Shanghvi founded Sun Pharmaceuticals in 1983 with a loan of Rs. 10,000 from his father. He started the company in Kolkata and later moved headquarters to Mumbai. Sun Pharma has grown to become the fifth largest drug maker in India through strategic acquisitions both in India and abroad. Shanghvi successfully turned around loss-making companies after acquiring them. Sun Pharma focuses on specialty and niche drugs, and over 70% of its sales come from India, though it also has operations in the US.
The document discusses the Indian pharmaceutical industry and Cadila Healthcare Limited. Some key points:
1. The Indian pharma industry is growing at 8-9% annually and meets 70% of India's drug demand. Cadila Healthcare is ranked 5th in the domestic market and manufactures drugs, vaccines, and consumer products.
2. Cadila spends over 12% of revenues on R&D and has a pipeline of biosimilars and vaccines. It focuses on new drug discovery and has over 950 researchers working across various therapeutic areas.
3. Financially, Cadila has grown its revenues and profits in recent years. Its domestic sales contribute 49% of total revenue. The company also pays
Ervas Pharmaceuticals' mission is to make herbal wellness accessible to everyone and promote the belief that good health should be available to all. The company produces herbal medicines with the goal of improving health and wellness. Ervas focuses on natural and herbal remedies to help more people access affordable healthcare options.
This document provides a history of the Indian pharmaceutical industry. It discusses how the industry grew after economic liberalization in the 1990s allowed Indian companies to enter generic drug manufacturing. It overtook the market share of multinational companies. The industry is now the 3rd largest producer globally by volume. It discusses the key players, regulations around patents, growth of exports, and challenges around research and development. It also provides an overview of the biotech sector in India and how it is growing but still smaller than the pharmaceutical industry.
This report is based on the summer training undertaken with lupin ltd anleshwar. It will be beneficial to the students who appear for training with lupin ankleshwar. The report also contains mini project on job rotation and transfer.
Ranbaxy is India's largest pharmaceutical company with a global presence in 43 countries. It produces generic medicines and has world-class manufacturing facilities. In 2008, Ranbaxy entered an alliance with Daiichi Sankyo to create an innovator and generic pharmaceutical powerhouse. The Indian pharmaceutical industry is the 3rd largest globally by volume and Ranbaxy is a leading player in this industry.
WealthZap Research Services-Cadila Heathcare Ltd MultiBagger Recommendation f...Saurabh
CHL is our typical Multibagger stock, but a Stock which is a Good Investment under current Market conditions. It has a presence in a space which offers enormous potential and is also trading at reasonable valuations which will deliver superior returns in the long run.
Core Investment Thesis :
The company is in healthcare space and is one of the fastest growing pharma companies among top-10 domestic peers. It currently ranks as the 4th largest pharmaceutical company in India with a market share of ~4.2%, based on domestic sales of formulations.
Ranbaxy Laboratories aims to become a research-based international pharmaceutical company. It has a strong presence in generics and is making progress in its drug discovery pipeline. Ranbaxy has grown organically and through acquisitions. It is India's largest pharmaceutical company and ranks 8th globally in generics. Ranbaxy continues to expand its global footprint and portfolio through strategic collaborations and alliances.
Lupin conducted a VRIO analysis to evaluate its resources and capabilities. Most factors like manufacturing units, human resources, products, and brand awareness were found to be neither rare nor difficult to imitate in the pharmaceutical industry. However, research and development, brand equity, and social equity were considered rare but imitable. While Lupin's organization supports its goals, its temporary competitive advantage in tuberculosis drugs suggests it focus more on specialty drugs and new markets to achieve sustained advantage.
Sun Pharma Advance Research Company Limited PresentationSubhashish Mondal
Sun Pharma Advance Research Company Limited (SPARC) is a leading pharmaceutical R&D company. This presentation is based on the solution faced by the company for last couple of years.
- Aurobindo Pharma is an Indian pharmaceutical company with a global presence in generic drug manufacturing.
- Its US business is a major growth driver, contributing 45% of sales, and it expects to launch 30-40 new products in the US in FY2017.
- It acquired Actavis' European operations in FY2015, turning around its European business which is now its second largest market.
- The company is entering more complex drug areas like peptides and controlled substances which have limited competition.
Sun pharma financial analysis 2008-2017Kushal Shah
This is the financial analysis of sun pharmaceutical india ltd..financial analyis is use for check all the profits and loss during 10 years.pharmaceutical sector affects on a particular pharma company.chages in corporate governance and csr activity can affect more on this analysis.some of the major ratios can affect on shareholders,competitiors.share holders watch it and buy and sell sun pharma companies share.so comment below after watch this ppt.thank you.
Business development of sunpharma presentation 3.pptxdmrjput
Sun Pharmaceutical Industries Ltd has grown through strategic acquisitions and alliances over the years. The document outlines Sun Pharma's acquisitions from 1996-2019 which expanded their manufacturing infrastructure, therapeutic coverage, and global presence. It also discusses how Sun Pharma focuses on business development through R&D investment, market segmentation, strategic partnerships, and intellectual property protection. Examples provided include the Ranbaxy acquisition and collaborations with MSD, Intrexon, Merck, and others.
This document provides information about Ranbaxy Laboratories Limited, including its group members, industry profile, company profile, vision, mission, and key areas like marketing, HR, finance, and recent news. It discusses that Ranbaxy is India's largest pharmaceutical company, ranked 8th globally in generics. It has manufacturing in 11 countries and a presence in 49 countries. The company aims to achieve customer satisfaction and be a responsible corporate citizen.
Sun Pharmaceuticals was founded in 1983 and has since grown to be one of the largest pharmaceutical companies globally through strategic mergers and acquisitions. Some of its most significant acquisitions include Ranbaxy Laboratories in 2014, which made it the largest pharmaceutical company in India. Sun Pharma focuses on generic and specialty drugs and generates most of its revenue from sales in the United States. It employs over 32,000 people worldwide and achieved $166 billion in revenue in 2013-2014 through its global manufacturing and distribution network. The company's leadership emphasizes the importance of speed, perfection, and building a strong team to drive continued growth.
Aurobindo Pharma Ltd. is an Indian pharmaceutical company established in 1986 that focuses on formulations. It has a vertically integrated business with in-house R&D and manufacturing approved by major global regulatory bodies. Aurobindo exports medications to over 125 countries, with international operations accounting for over 70% of its revenues. It has over 7,800 employees including 700 scientists and facilities across 5 million square meters.
Group No. 4 set a vision in 2007 to achieve $1 billion in sales, dubbed the "Healthy Billion." In fiscal year 2010-2011, they crossed the $1 billion mark, achieving their goal. They now aspire to reach $3 billion in sales by 2015. The company maintained strong growth across its business segments including India formulations, international formulations, API and intermediates, animal health, and wellness. New product launches and geographic expansions contributed to the financial success.
Fundamental Analysis of Aurobindo Pharma StockAshish Sharma
The document analyzes the financial performance of Aurobindo Pharma, an Indian pharmaceutical company founded in 1986. It provides financial ratios for Aurobindo compared to industry averages from 2010-2014, showing that Aurobindo generally performs better than average across current ratio, quick ratio, debt-equity ratio, interest coverage ratio, debtors turnover ratio, creditors turnover ratio, stock turnover ratio, gross profit ratio, net profit ratio, return on assets, return on capital employed, price-earnings ratio, earnings per share, book value per share, dividend per share and dividend yield ratio. The document also lists cash flow figures for Aurobindo from 2009-2013.
Pankaj Patel holds degrees in pharmacy and pursued further studies in pharmaceutical technology. He is the Chairman and Managing Director of Cadila Healthcare Limited and its subsidiary Zydus Animal Health Limited. He has led the company's acquisitions, received several honors, and helped develop an H1N1 vaccine. His career has been defined by great leadership, visionary strategy, determination, innovation, and a simple approach.
Ranbaxy is India's largest pharmaceutical company with a global footprint in 43 countries. It has a diverse product portfolio and strong R&D capabilities. In 2011, Ranbaxy recorded global sales of $2.1 billion, with emerging and developed markets each contributing around 47% and 46% respectively. Ranbaxy aims to grow organically and inorganically, focusing on high-growth areas like biologics and injectables. It also has a hybrid business model through its alliance with Daiichi Sankyo to create an innovator and generic powerhouse. Ranbaxy emphasizes R&D as a strategic priority and has over 1,200 personnel dedicated to research.
Dilip Shanghvi is the founder and managing director of Sun Pharmaceuticals, which he started in 1982 with Rs. 10,000 capital. Under his leadership, Sun Pharmaceuticals has grown to become India's largest drugmaker and most valuable pharmaceutical company. Shanghvi launched his career helping his father's wholesale drugs business and realized he could manufacture his own drugs. Through strategic acquisitions over the decades, Sun Pharmaceuticals now has a global presence and Shanghvi has a net worth of over $18 billion, making him one of Asia's richest self-made billionaires.
Dilip Shanghvi founded Sun Pharmaceuticals in 1983 with a loan of Rs. 10,000 from his father. He started the company in Kolkata and later moved headquarters to Mumbai. Sun Pharma has grown to become the fifth largest drug maker in India through strategic acquisitions both in India and abroad. Shanghvi successfully turned around loss-making companies after acquiring them. Sun Pharma focuses on specialty and niche drugs, and over 70% of its sales come from India, though it also has operations in the US.
The document discusses the Indian pharmaceutical industry and Cadila Healthcare Limited. Some key points:
1. The Indian pharma industry is growing at 8-9% annually and meets 70% of India's drug demand. Cadila Healthcare is ranked 5th in the domestic market and manufactures drugs, vaccines, and consumer products.
2. Cadila spends over 12% of revenues on R&D and has a pipeline of biosimilars and vaccines. It focuses on new drug discovery and has over 950 researchers working across various therapeutic areas.
3. Financially, Cadila has grown its revenues and profits in recent years. Its domestic sales contribute 49% of total revenue. The company also pays
Ervas Pharmaceuticals' mission is to make herbal wellness accessible to everyone and promote the belief that good health should be available to all. The company produces herbal medicines with the goal of improving health and wellness. Ervas focuses on natural and herbal remedies to help more people access affordable healthcare options.
This document provides a history of the Indian pharmaceutical industry. It discusses how the industry grew after economic liberalization in the 1990s allowed Indian companies to enter generic drug manufacturing. It overtook the market share of multinational companies. The industry is now the 3rd largest producer globally by volume. It discusses the key players, regulations around patents, growth of exports, and challenges around research and development. It also provides an overview of the biotech sector in India and how it is growing but still smaller than the pharmaceutical industry.
This report is based on the summer training undertaken with lupin ltd anleshwar. It will be beneficial to the students who appear for training with lupin ankleshwar. The report also contains mini project on job rotation and transfer.
Ranbaxy is India's largest pharmaceutical company with a global presence in 43 countries. It produces generic medicines and has world-class manufacturing facilities. In 2008, Ranbaxy entered an alliance with Daiichi Sankyo to create an innovator and generic pharmaceutical powerhouse. The Indian pharmaceutical industry is the 3rd largest globally by volume and Ranbaxy is a leading player in this industry.
WealthZap Research Services-Cadila Heathcare Ltd MultiBagger Recommendation f...Saurabh
CHL is our typical Multibagger stock, but a Stock which is a Good Investment under current Market conditions. It has a presence in a space which offers enormous potential and is also trading at reasonable valuations which will deliver superior returns in the long run.
Core Investment Thesis :
The company is in healthcare space and is one of the fastest growing pharma companies among top-10 domestic peers. It currently ranks as the 4th largest pharmaceutical company in India with a market share of ~4.2%, based on domestic sales of formulations.
Ranbaxy Laboratories aims to become a research-based international pharmaceutical company. It has a strong presence in generics and is making progress in its drug discovery pipeline. Ranbaxy has grown organically and through acquisitions. It is India's largest pharmaceutical company and ranks 8th globally in generics. Ranbaxy continues to expand its global footprint and portfolio through strategic collaborations and alliances.
Lupin conducted a VRIO analysis to evaluate its resources and capabilities. Most factors like manufacturing units, human resources, products, and brand awareness were found to be neither rare nor difficult to imitate in the pharmaceutical industry. However, research and development, brand equity, and social equity were considered rare but imitable. While Lupin's organization supports its goals, its temporary competitive advantage in tuberculosis drugs suggests it focus more on specialty drugs and new markets to achieve sustained advantage.
Sun Pharma Advance Research Company Limited PresentationSubhashish Mondal
Sun Pharma Advance Research Company Limited (SPARC) is a leading pharmaceutical R&D company. This presentation is based on the solution faced by the company for last couple of years.
- Aurobindo Pharma is an Indian pharmaceutical company with a global presence in generic drug manufacturing.
- Its US business is a major growth driver, contributing 45% of sales, and it expects to launch 30-40 new products in the US in FY2017.
- It acquired Actavis' European operations in FY2015, turning around its European business which is now its second largest market.
- The company is entering more complex drug areas like peptides and controlled substances which have limited competition.
Sun pharma financial analysis 2008-2017Kushal Shah
This is the financial analysis of sun pharmaceutical india ltd..financial analyis is use for check all the profits and loss during 10 years.pharmaceutical sector affects on a particular pharma company.chages in corporate governance and csr activity can affect more on this analysis.some of the major ratios can affect on shareholders,competitiors.share holders watch it and buy and sell sun pharma companies share.so comment below after watch this ppt.thank you.
Business development of sunpharma presentation 3.pptxdmrjput
Sun Pharmaceutical Industries Ltd has grown through strategic acquisitions and alliances over the years. The document outlines Sun Pharma's acquisitions from 1996-2019 which expanded their manufacturing infrastructure, therapeutic coverage, and global presence. It also discusses how Sun Pharma focuses on business development through R&D investment, market segmentation, strategic partnerships, and intellectual property protection. Examples provided include the Ranbaxy acquisition and collaborations with MSD, Intrexon, Merck, and others.
Here are some key facts and figures about the global pharmaceutical industry:
- The global pharmaceutical market was estimated to be worth around $1.2 trillion in 2020. It is projected to reach $1.6 trillion by 2026.
- The top 10 global pharmaceutical companies by revenue in 2020 were Johnson & Johnson, Pfizer, Roche, Sanofi, Novartis, Merck & Co., AbbVie, GSK, Amgen, and Gilead Sciences.
- The top three pharmaceutical markets by sales in 2020 were the US at $360 billion, China at $145 billion, and Japan at $102 billion.
- The US accounted for around 40% of global pharmaceutical spending in 2020, despite
Present Status and Scope of Pharmaceutical industry in IndiaMadhuraNewrekar
The Indian pharmaceutical industry came into existence in 1901, when Bengal Chemical & Pharmaceutical Company started its maiden operation in Calcutta.
The next few decades saw the pharmaceutical industry moving through several phases, largely in accordance with government policies. The development, present status and scope of pharmaceutical industry in India.
List Of Medicine Manufacturers in India | PharmaaddaAditiMehra14
This blog provides you the details about the Top Pharma Manufacturers in India with all the required details. For more details visit http://www.pharmaadda.in/list-of-medicine-manufacturers-in-india
Manoj Kumar, general manager of sales at Parkin Laboratories, must decide on revised sales targets for the final quarter of 2012. While the company achieved 91% of its sales target for the first three quarters with 10.6% growth, the overall growth target is 20%. Kumar must determine how to make the regional sales managers more productive to achieve targets and drive the required growth. He is also deciding whether to launch a new drug in December as the sales team works to achieve their current targets. Finally, Kumar must determine the best strategy to help the medical representatives and district sales managers succeed in the last quarter.
Ranbaxy Laboratories Ltd. was India’s largest pharmaceutical company in 2006, with global revenue of $1.3 billion. The document discusses Ranbaxy's history and growth strategy under different CEOs from the 1990s-2000s. It summarizes how Parvinder Singh expanded internationally through acquisitions and joint ventures, establishing manufacturing facilities around the world. His successors Devinder Singh Brar and Brian W Tempest continued the global strategy, further growing international sales especially in the US through generic drugs.
This document provides information about Sun Pharmaceutical Industries Ltd and Lupin Ltd, two major pharmaceutical companies in India. It discusses their histories, goals, visions, missions, boards of directors, and key milestones. Some notable points are that Sun Pharma was established in 1983 and is now India's largest chronic prescription drug company, while Lupin was founded in 1968 and is the 3rd largest pharmaceutical company in India and 7th largest generic drug maker globally. Both companies have grown through acqu
Top generic pharma companies in india pptAditiMehra14
I have provided the analyzed list of Top Generic Pharma Companies in India. Check blog and choose right generic pharma companies franchise for PCD business. For more information visit http://www.pharmaadda.in/top-generic-pharma-companies-in-india
Novartis has been operating in India since 1947 through various entities. It has a presence in pharmaceuticals, generics, vaccines, over-the-counter medicines, and eye care. Novartis' mission is to discover, develop, and market innovative products to prevent and cure diseases while enhancing quality of life. Its vision is to provide shareholder returns through outstanding performance. Novartis invests heavily in research and development through its institute and sees R&D as key to innovation and meeting unmet medical needs.
The document discusses marketing strategies used by pharmaceutical companies. It notes that companies are shifting from acute therapies to focusing more on chronic therapies that require long-term treatment. This allows companies to build more stable customer bases. The document also outlines some of the challenges companies face, such as increased competition, high costs of research and development, and complex decision-making processes involving doctors, patients, and other stakeholders. It discusses two common business models - the "super core model" involving a small number of highly successful chronic drugs, and the "core model" involving marketing a larger number of acute drugs.
The document discusses marketing strategies used by pharmaceutical companies. It notes that companies are shifting from acute therapies to focusing more on chronic therapies. This represents a long-term strategy change as chronic therapies require doctors to prescribe the same drugs for longer periods. The document also outlines some of the challenges pharmaceutical companies face in marketing to different customers in the supply chain from doctors to patients. It discusses strategies around patents, research and development, and pursuing either a "super core" model focused on a small number of chronic drugs or a "core" model marketing more acute drugs.
The document provides information about the pharmaceutical industry in India. It discusses that India has the 4th largest pharmaceutical industry in the world. It then lists the top 6 pharmaceutical companies in India by market capitalization - Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Lupin Pharmaceutical Ltd., Cipla, Dr. Reddy's Laboratories Ltd., and Mankind Pharma Pvt Ltd. The document also discusses the top pharmaceutical companies located in Haryana and neighboring states like Alpha Pharmaceuticals, Indian Drugs and Pharmaceuticals, and Swiss Biotech. It mentions how the pharmaceutical sector is doing well in India with an expected growth rate of 30% and the market reaching $100 billion by 20
Sun pharma- A complete company review, analysis of crisis and realistic recom...TilikaChawda
Sun pharma has been the most talked about Indian pharma company for being in the news several times for its unresolved issues with the US FDA regarding the Halol and Mohali plant.
This presentation has analysed the situation and it suggests various solutions for the same.
Pharma third party manufacturing companies in Baddi | PharmaaddaAditiMehra14
The document discusses top 10 pharma third party manufacturing companies located in Baddi, Himachal Pradesh, India. Baddi is a major hub for the pharmaceutical industry, contributing 35% of drugs manufactured domestically in Asia. The listed companies provide services like contract manufacturing, manufacturing medications, tablets and capsules to other pharmaceutical companies. They have facilities approved by regulatory bodies like US FDA, EU-GMP and adhere to Good Manufacturing Practices. Choosing one of these third party manufacturers can help companies expand their business and produce quality medicines at affordable costs.
The document summarizes a research study conducted in Ahmedabad, India. The study aimed to understand the demand and supply of narcotic analgesic drugs (morphine, pethidine, fentanyl) in the city. It also sought to understand doctors' preferences for narcotic analgesics versus non-narcotic drugs, and hurdles faced by doctors and retailers in using and selling regulated narcotic drugs. The researcher administered questionnaires to anesthesiologists to understand demand, and retailers to understand supply. Most responding doctors preferred narcotic analgesics to non-narcotic drugs.
Lupin is an Indian pharmaceutical company established in 1968. It has a presence in over 100 markets worldwide and generates revenue through generic and branded formulations, APIs, and OTC products. In FY 2021, Lupin reported revenues of approximately $2.2 billion and net profits of $130 million. It focuses on therapeutic areas like cardiovascular, CNS, and respiratory drugs. Lupin emphasizes quality, compliance, ethics, and CSR initiatives while facing challenges from regulatory changes and competition in key markets like North America and Europe.
PRESENT SCENARIO OF INDIAN PHARMACEUTICAL INDUSTRY IN VIEW OF GLOBAL ...sridivyaannavarapu
THE INDIAN GOVERNMENT HAS STARTED TO ENCOURAGE THE GROWTH OF DRUG MANUFACTURING BY INDIAN COMPANIES IN THE EARLY 1960s. AT PRESENT THERE ARE MANY NUMBER OF PHARMACEUTICAL COMPANIES IN INDIA WITH MANY NOVEL DRUG INVENTORIES
Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company founded by Anji Reddy. It began as an API supplier in India and exported to less regulated markets, using profits to gain approvals in markets like the US and Europe. Today it has over 15,000 employees across 17 countries and manufactures over 190 medications and 60 APIs. It focuses on generics and has expanded into areas like biotechnology and diagnostics through strategic collaborations.
Similar to Sun pharmaceutical ( international marketing ) term paper (20)
The best massage spa Ajman is Chandrima Spa Ajman, which was founded in 2023 and is exclusively for men 24 hours a day. As of right now, our parent firm has been providing massage services to over 50,000+ clients in Ajman for the past 10 years. It has about 8+ branches. This demonstrates that Chandrima Spa Ajman is among the most reasonably priced spas in Ajman and the ideal place to unwind and rejuvenate. We provide a wide range of Spa massage treatments, including Indian, Pakistani, Kerala, Malayali, and body-to-body massages. Numerous massage techniques are available, including deep tissue, Swedish, Thai, Russian, and hot stone massages. Our massage therapists produce genuinely unique treatments that generate a revitalized sense of inner serenely by fusing modern techniques, the cleanest natural substances, and traditional holistic therapists.
Michigan HealthTech Market Map 2024. Includes 7 categories: Policy Makers, Academic Innovation Centers, Digital Health Providers, Healthcare Providers, Payers / Insurance, Device Companies, Life Science Companies, Innovation Accelerators. Developed by the Michigan-Israel Business Accelerator
Joker Wigs has been a one-stop-shop for hair products for over 26 years. We provide high-quality hair wigs, hair extensions, hair toppers, hair patch, and more for both men and women.
About this webinar: This talk will introduce what cancer rehabilitation is, where it fits into the cancer trajectory, and who can benefit from it. In addition, the current landscape of cancer rehabilitation in Canada will be discussed and the need for advocacy to increase access to this essential component of cancer care.
2024 HIPAA Compliance Training Guide to the Compliance OfficersConference Panel
Join us for a comprehensive 90-minute lesson designed specifically for Compliance Officers and Practice/Business Managers. This 2024 HIPAA Training session will guide you through the critical steps needed to ensure your practice is fully prepared for upcoming audits. Key updates and significant changes under the Omnibus Rule will be covered, along with the latest applicable updates for 2024.
Key Areas Covered:
Texting and Email Communication: Understand the compliance requirements for electronic communication.
Encryption Standards: Learn what is necessary and what is overhyped.
Medical Messaging and Voice Data: Ensure secure handling of sensitive information.
IT Risk Factors: Identify and mitigate risks related to your IT infrastructure.
Why Attend:
Expert Instructor: Brian Tuttle, with over 20 years in Health IT and Compliance Consulting, brings invaluable experience and knowledge, including insights from over 1000 risk assessments and direct dealings with Office of Civil Rights HIPAA auditors.
Actionable Insights: Receive practical advice on preparing for audits and avoiding common mistakes.
Clarity on Compliance: Clear up misconceptions and understand the reality of HIPAA regulations.
Ensure your compliance strategy is up-to-date and effective. Enroll now and be prepared for the 2024 HIPAA audits.
Enroll Now to secure your spot in this crucial training session and ensure your HIPAA compliance is robust and audit-ready.
https://conferencepanel.com/conference/hipaa-training-for-the-compliance-officer-2024-updates
We are one of the top Massage Spa Ajman Our highly skilled, experienced, and certified massage therapists from different corners of the world are committed to serving you with a soothing and relaxing experience. Luxuriate yourself at our spas in Sharjah and Ajman, which are indeed enriched with an ambiance of relaxation and tranquility. We could confidently claim that we are one of the most affordable Spa Ajman and Sharjah as well, where you can book the massage session of your choice for just 99 AED at any time as we are open 24 hours a day, 7 days a week.
Visit : https://massagespaajman.com/
Call : 052 987 1315
Can Allopathy and Homeopathy Be Used Together in India.pdfDharma Homoeopathy
This article explores the potential for combining allopathy and homeopathy in India, examining the benefits, challenges, and the emerging field of integrative medicine.
Hypertension and it's role of physiotherapy in it.Vishal kr Thakur
This particular slides consist of- what is hypertension,what are it's causes and it's effect on body, risk factors, symptoms,complications, diagnosis and role of physiotherapy in it.
This slide is very helpful for physiotherapy students and also for other medical and healthcare students.
Here is summary of hypertension -
Hypertension, also known as high blood pressure, is a serious medical condition that occurs when blood pressure in the body's arteries is consistently too high. Blood pressure is the force of blood pushing against the walls of blood vessels as the heart pumps it. Hypertension can increase the risk of heart disease, brain disease, kidney disease, and premature death.
DECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdfDr Rachana Gujar
Introduction: Substance use education is crucial due to its prevalence and societal impact.
Alcohol Use: Immediate and long-term risks include impaired judgment, health issues, and social consequences.
Tobacco Use: Immediate effects include increased heart rate, while long-term risks encompass cancer and heart disease.
Drug Use: Risks vary depending on the drug type, including health and psychological implications.
Prevention Strategies: Education, healthy coping mechanisms, community support, and policies are vital in preventing substance use.
Harm Reduction Strategies: Safe use practices, medication-assisted treatment, and naloxone availability aim to reduce harm.
Seeking Help for Addiction: Recognizing signs, available treatments, support systems, and resources are essential for recovery.
Personal Stories: Real stories of recovery emphasize hope and resilience.
Interactive Q&A: Engage the audience and encourage discussion.
Conclusion: Recap key points and emphasize the importance of awareness, prevention, and seeking help.
Resources: Provide contact information and links for further support.
The facial nerve, also known as cranial nerve VII, is one of the 12 cranial nerves originating from the brain. It's a mixed nerve, meaning it contains both sensory and motor fibres, and it plays a crucial role in controlling various facial muscles, as well as conveying sensory information from the taste buds on the anterior two-thirds of the tongue.
Letter to MREC - application to conduct studyAzreen Aj
Application to conduct study on research title 'Awareness and knowledge of oral cancer and precancer among dental outpatient in Klinik Pergigian Merlimau, Melaka'
International Cancer Survivors Day is celebrated during June, placing the spotlight not only on cancer survivors, but also their caregivers.
CANSA has compiled a list of tips and guidelines of support:
https://cansa.org.za/who-cares-for-cancer-patients-caregivers/
Can coffee help me lose weight? Yes, 25,422 users in the USA use it for that ...nirahealhty
The South Beach Coffee Java Diet is a variation of the popular South Beach Diet, which was developed by cardiologist Dr. Arthur Agatston. The original South Beach Diet focuses on consuming lean proteins, healthy fats, and low-glycemic index carbohydrates. The South Beach Coffee Java Diet adds the element of coffee, specifically caffeine, to enhance weight loss and improve energy levels.
TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardso...rightmanforbloodline
TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardson, Verified Chapters 1 - 18, Complete Newest Version
TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardson, Verified Chapters 1 - 18, Complete Newest Version
TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardson, Verified Chapters 1 - 18, Complete Newest Version
Sun pharmaceutical ( international marketing ) term paper
1. Course Code: MKT 625J Course Title: International Marketing
Course Instructor: Mr. MunishSaini
Academic Task Title:Term Paper
Date ofAllotment: Date of Submission:02nd
May2018
Student’sRoll no: A-18 Student’sReg. no: 11611433
Evaluation Parameters:
Learning Outcomes:(Studentto write brieflyabout learningsobtainedfrom the academic tasks)
Declaration: I declare thatthisAssignmentismyindividual work.Ihave notcopieditfromanyother
student’sworkorfrom anyothersource exceptwhere due acknowledgementismade explicitlyinthe
text,norhas any part beenwrittenforme byany otherperson.
Student’sSignature: Anirudh Vashistha (02-05-18)
Evaluator’s comments (ForInstructor’s use only)
General Observations Suggestionsfor Improvement Best part ofassignment
Evaluator’s Signature and Date:
Marks Obtained: _______________ Max. Marks: ______________
2. SUN PHARMACEUTICAL
Dilip was born in Mumbai. His family later moved to Kolkata. He started off by helping his
father’s wholesale pharma business in Kolkata (then Calcutta). After Graduating from Calcutta
University in the stream of commerce, he started his own business in Kolkata with one
employee, where he marketed and sold psychiatry medicine. He then came to Mumbai, and set
up his first factory in Vapi, Gujarat.
Sun Pharmaceuticals was established by Mr. Dilip Shanghvi in 1983 in Vapi with five products
to treat psychiatry ailments. Cardiology products were introduced in 1987 followed
by gastroenterology products in 1989. Today, it is the largest chronic prescription company in
India and a market leader in psychiatry, neurology, cardiology, orthopedics, ophthalmology,
gastroenterology and nephrology.
The 2014 acquisition of Ranbaxy has made the company the largest pharma company in India,
the largest Indian pharma company in the US, and the 4th largest specialty generic company
globally.
Over 72% of Sun Pharma sales are from markets outside India, primarily in the US. The US is
the single largest market, accounting for about 50% turnover; in all, formulations or finished
dosage forms, account for 93% of the turnover. Manufacturing is across 26 locations, including
plants in the US, Canada, Brazil, Mexico and Israel. In the US, the company markets a large
basket of generics, with a strong pipeline awaiting approval from the U.S. Food and Drug
Administration (FDA).
Sun Pharma was listed on the stock exchange in 1994 in an issue oversubscribed 55 times. The
founding family continues to hold a majority stake in the company. Today Sun Pharma is the
second largest and the most profitable pharmaceutical company in India, as well as the largest
pharmaceutical company by market capitalisation on the Indian exchanges.
The Indian pharmaceutical industry has become the third largest producer in the world in terms
of volumes and is poised to grow into an industry of $20 billion in 2015 from the current
turnover of $12 billion. In terms of value India still stands at number 14 in the world.
In 2009 Sun Pharma's Caraco Pharmaceutical's plant in Detroit was closed due to unsanitary
conditions resulting in the seizure of $20 million of drugs by the FDA for contamination issues.
3. In December 2016 the FDA sent Sun a warning letter about nine violations at its manufacturing
plant in Halol.
Sun Pharma requested the USFDA to withdraw approval for 28 Abbreviated New Drug
Applications (ANDAs) belonging to its wholly owned subsidiary Ranbaxy Laboratories.
4. VISION
Reaching people and touching lives globally as a leading provider of Valued Medicines.
SUNOLOGY of the company
Sunology- it’s a combination of two words, Sun and ideology is at the core of Sun. Humility,
Integrity, Passion, & Innovation together from Sunology. It is a way of life at Sun.
HUMILITY
Under promise and over deliver.
Let your work speak for you.
Always put ‘we’ before me.
Learn from mistakes.
INTEGRITY
Do the right thing with conviction & without fear.
Practice honesty, impartiality & fairness at all time.
Adhere to strong ethical and moral standards.
Courage to call-out what is not right.
PASSION
Infuse energy in everything that you do.
Walk that extra mile.
Inspire others.
Do your best in every situation.
INNOVATION
Strive to implement new ideas and technologies to meet unmet needs.
Encourage others to think out-of-the-box.
Do not limit yourself.
Believe in raising the bar every time.
5. JOURNEY OF SUNPHARMACEUTICAL
Sun Pharmaceutical Industries Ltd. is the fifth largest speciality generic pharmaceutical company
in the world. The company manufactures and markets a large basket of pharmaceutical
formulations covering a broad spectrum of chronic and acute therapies. It includes generics
branded generics complex or difficult to make technology intensive products over-the-counter
(OTC) products anti-retrovirals (ARVs) Active Pharmaceutical Ingredients (APIs) and
intermediates. The product portfolio of over 2000 high quality molecules covers multiple dosage
forms including tablets capsules injectables inhalers ointments creams and liquids.
The products cater to a vast range of therapeutic segments covering psychiatry anti-infectives
neurology cardiology orthopaedic diabetology gastroenterology ophthalmology nephrology
urology dermatology gynaecology respiratory oncology dental and nutritionals. The company
has global presence with 41 manufacturing facilities across the world. India and the US are two
predominant markets accounting for nearly 70% of the company's revenue. The company has a
robust product pipeline and established presence in Europe and high-growth emerging markets
like Russia Romania South Africa Brazil and Mexico. The company has entered into a joint-
venture agreement with MSD (Merck) to develop and bring differentiated branded generics to
emerging markets. Sun Pharmaceutical Industries invests around 7-8% of its global revenue each
year in R&D. The R&D capabilities span the development of differentiated products such as
liposomal products inhalers lyophilized injections and nasal sprays besides controlled release
dosage forms.
Sun Pharmaceutical Industries Ltd was incorporated in the year 1983. The company began
operations in Kolkata with just 5 products to treat psychiatry ailments. They set up a compact
manufacturing facility for tablets/capsules at Vapi. Sales were initially limited to two states in
Eastern India. In the year 1986 the company set up an administrative office in Mumbai. They
extended the customer coverage to select cities in Western India. In the year 1987 they rolled out
their marketing operations nation-wide.In the year 1988 the company launched Monotrate and
Angizem products. In the year 1989 they introduced Products used in gastroenterology. They
moved their corporate office to Baroda. Also they began exporting their products to neighboring
6. countries. In the year 1998 the company established their first research center SPARC and this
created the base for strong product and process development that enabled growth in the
subsequent years. Also they began office in Moscow.
In the year 1994 the company was listed on the main stock exchanges in India. They started
production in a dosage form plant at Silvassa. Also they completed the major expansion at Vapi
plant. In the year 1995 the company's first API plant at Panoli started production. Also a new
division Azura was begun for cardiology products. Inca a new division to market critical care
medication to intensive care units began operations. They strengthened the international
marketing with offices in Ukraine and Belarus. In the year 1996 the company acquired an API
plant at Ahmednagar from the multinational Knoll Pharmaceutical and expanded and
substantially upgraded for regulated markets with capacity addition over the years across
differentiated API lines such as anticancers and peptides. Also the company acquired equity
stake in Gujarat Lyka Organics Ltd. a manufacturer of Cephalexin Active with a USFDA
approval for the intermediate 7ADCA.In the year 1997 the company's headquarters was shifted
to Mumbai India's commercial capital. Also they began the first of their international
acquisitions with an initial $7.5 million investment in Caraco Detroit. Also they took equity stake
in MJ Pharma a manufacturer of several dosage form lines with UK MHRA approval for
Cephalexin capsules.
The company acquired TDPL with an extensive product offering and its portfolio streamlined. In
the year 1998 the company acquired a basket of products including several respiratory/asthma
brands acquired from Natco Pharma. Their new formulation plant at Silvassa commenced
operations. In the year 2001 the company built a new formulation plant in Dadra. Also the
erstwhile TDPL division was renamed Spectra. A new division Arian targeting
cardiologists/physicians and diabetologists was launched. In the year 2004 the company acquired
common stock and options from 2 large shareholders of Caraco increasing stake to over 60%
from 44% at a total outlay of about $42 million. The upgraded and expanded formulation site in
Halol India (the erstwhile MJ Pharma site) received approval from USFDA UK MHRA South
African MCC Brazilian ANVISA and Columbian INVIMA. During the year the company
completed the construction at a formulation manufacturing site at Jammu.
7. They commissioned their first joint venture manufacturing unit in Dhaka Bangladesh. Also two
of their API factories received USFDA approval taking the total number of US FDA approved
sites to three. The company acquired a Cephalosporin Active manufacturer Phlox Pharma with
European approval for cefuroxime axetil amorphous.
In December 2004 a research centre spread over 16 acres was inaugurated by the President of
India with special lab space for drug discovery and innovation. In the year 2005 the company
bought a plant in Bryan Ohio US and the business of ICN Hungary from Valeant Pharma. In
December 2005 they acquired the intellectual property and assets of Able Labs from the US
District Bankruptcy court in New Jersey. In the year 2007 the company de-merged the
innovative research and business into a new company SPARC Ltd. SPARC Ltd was listed on the
stock exchanges in India the first pure research company to be so listed.
In May 2007 the company along with their subsidiaries signed definitive agreements to acquire
Taro Pharmaceutical Industries Ltd. a multinational generic manufacturer with established
subsidiaries manufacturing and products across the US Israel Canada for $454 million.In
November 2008 the company along with their subsidiaries acquired 100% ownership of Chattem
Chemicals Inc. a narcotic raw material importer and manufacturer of controlled substances with
an approved API facility in Tennessee. This offers vertical integration for its controlled
substance dosage form business in the US. In September 2010 the company acquired Taro
Pharmaceuticals. This acquisition doubled the size of their US business and brought them a
range of generics including a strong line of dermatologicals.
In April 2011 MSD in India and Sun Pharmaceutical Industries Ltd announced formation of an
India-specific strategic partnership agreement under which Sun Pharma will have the right to
market promote and distribute MSD's diabetes products sitagliptin and sitagliptin plus metformin
under different brand names in India. In June 14 2011 Caraco Pharmaceutical Laboratories Ltd
(Caroco) merged with a subsidiary of the company. Thus Caraco became a wholly owned
subsidiary of the company.In 2012 Sun Pharma bagged USFDA approval for its AND
Application for generic Zyprexa. The company also acquired URL generic business from Takeda
during the year under review. In 2013 the company announced US FDA approval for generic
8. Cymbalta. The company and Intrexon formed Joint Venture to Develop New Class of
Therapeutics for Ocular Diseases. The Company announces USFDA approval for generic
Prevacid generic DoxilAr and generic DepoAr-Testosterone Injection.
The company also Announces 1:1 Bonus during the year. The company also announces
Tentative USFDA approval for generic Januvia & Glumetza. In 2014 the company announced
US FDA approval for generic Temodar. The company acquires Pharmalucence during the year.
The company and Merck & Co. Inc. enter into Licensing Agreement for Tildrakizumab during
the year under review. The Board of Directors of the Company at its Meeting held on April 06
2014 has approved the scheme of arrangement between Ranbaxy Laboratories Limited and the
Company under the provisions of the sections 391 to 394 and other applicable provisions of the
Companies Act 1956 and corresponding provisions of the Companies Act 2013 subject to receipt
of necessary approvals consents and filings.
In 2015 the company receives US FTC clearance for Ranbaxy acquisition. The company and
AstraZeneca enter into distribution agreement for ticagrelor in India during the year. SPARC
Licenses Xelpros (Latanoprost BAK-free) to Sun Pharma. During the year Hon'ble High Court
of Gujarat at Ahmedabad has approved the Scheme of Amalgamation of Sun Pharma Global Inc.
(SPGI) wholly-owned subsidiary of the Company. The company also announces US FDA
Approval for Ximino TM. The company also announces another successful completion of
Opiates business acquisition in Australia and also acquires InSite Vision Incorporated. The
company announces Absorica patent litigation settlement during the year under review.
On 10 December 2015 Sun Pharmaceutical Industries announced that it has entered into a
tripartite research and option agreement with Israel-based Weizmann Institute of Science and
Spain's Health Research Institute of Santiago de Compostela (IDIS) to develop breakthrough
products for the treatment of neurological diseases like brain stroke as well as glioblastoma a
lethal brain cancer. On 14 December 2015 Sun Pharmaceutical Industries announced that as a
part of its manufacturing consolidation in the US one of its wholly owned subsidiaries has
entered into an agreement with Nostrum Laboratories Inc. (Nostrum) for the divestment of the
9. Bryan (Ohio) unit in the US. As a part of the agreement the Sun Pharma subsidiary has divested
this unit as a going concern along with the employees and related products to Nostrum.
On 19 December 2015 Sun Pharmaceutical Industries announced that it has received a Warning
Letter from the USFDA as a result of the September 2014 inspection for its facility located at
Halol Gujarat in India. Post the September 2014 inspection the US FDA has withheld future
product approvals from the Halol facility. Sun Pharma said that the company expects to request a
re-inspection by USFDA upon completion of its remediation commitments. Sun Pharma also
said at that time that the Halol facility will continue to supply important drug products to meet its
obligations to its customers and the patients who use the drugs in the United States and around
the world.
On 23 March 2016 Sun Pharma and AstraZeneca Pharma India Limited announced a partnership
for the distribution of dapagliflozin an innovative Type 2 diabetes medicine in India.
Dapagliflozin is AstraZeneca India's leading diabetes medicine. Under the agreement Sun
Pharma will promote and distribute dapagliflozin under the brand name Oxra.
AstraZeneca India markets dapagliflozin under the brand name Forxiga and under the terms of
the agreement both companies will promote market and distribute dapagliflozin in India under
different brand names. AstraZeneca will retain the intellectual property rights to dapagliflozin.
Sun Pharma will also gain the rights to promote and distribute the combination of dapagliflozin
with metformin under the brand name Oxramet after requisite regulatory approval.On 29 March
2016 Sun Pharma announced the acquisition of 14 established prescription brands from Novartis
AG and Novartis Pharma AG in Japan. According to the agreements entered into between the
parties a wholly-owned subsidiary of Sun Pharma will acquire the portfolio consisting of 14
established prescription brands from Novartis for a cash consideration of US$ 293 million. These
brands have combined annualized revenues of approximately US$ 160 million and address
medical conditions across several therapeutic areas.
Under the terms of the agreements Novartis will continue to distribute these brands for a certain
period pending transfer of all marketing authorizations to Sun Pharma's subsidiary. The acquired
10. brands will be marketed by a reliable and established local marketing partner under the Sun
Pharma label. The local marketing partner will also be responsible for distribution of the
brands.On 4 May 2016 Sun Pharma and International Centre for Genetic Engineering and
Biotechnology (ICGEB) signed an agreement to develop a novel botanical drug for treatment of
dengue. Through this agreement Sun Pharma will follow up on earlier pre-clinical collaboration
between ICGEB and erstwhile Ranbaxy Laboratories. Sun Pharma will develop Cipa a botanical
drug following a drug registration process similar to a new chemical entity consisting of all
required in-vitro in-vivo pre-clinical and clinical studies meeting all regulatory standards of India
and other regulatory agencies worldwide.
A botanical drug is a plant-derived medicinal product that is intended for use in the diagnosis
cure mitigation treatment or prevention of disease in humans. On 4 June 2016 Sun Pharma
announced that as a part of its manufacturing consolidation in the US one of its wholly owned
subsidiaries has entered into an agreement with Frontida BioPharm Inc. (Frontida) for
divestment of its two oral solid dosage manufacturing facilities located at Philadelphia PA and
Aurora IL both in the US along with 15 related pharmaceutical products. In connection with the
transaction Frontida has agreed to continue manufacturing certain products for Sun Pharma at
these facilities on a contract basis for a predetermined period.
The Board of Directors of Sun Pharma at its meeting held on 23 June 2016 approved buyback of
fully paid up equity shares of the company through the tender offer route at Rs 900 per share.
The purpose of the buyback is to return surplus funds to the equity shareholders and thereby
enhancing the overall returns to shareholders. On 18 July 2016 Sun Pharma and Sun Pharma
Advanced Research Company Ltd. (SPARC) announced a licensing arrangement for SPARC's
ELEPSIA XR (Levetiracetam Extended Release tablets). As per the agreement SPARC will
license ELEPSIA to a wholly-owned subsidiary of Sun Pharma for the US market. SPARC will
receive an up-front payment of US$10 million from Sun Pharma. It is also eligible for certain
additional milestone payments and defined royalties linked to any future sales of ELEPSIA
XR.On 27 July 2016 Sun Pharma and Almirall announced a licensing agreement on the
development and commercialization of tildrakizumab for psoriasis in Europe. Under terms of the
license agreement Almirall will pay Sun Pharma an initial upfront payment of US $50 million.
11. Sun Pharma will be eligible to receive development and regulatory milestone payments and
additionally sales milestone payments and royalties on net sales. Almirall will be able to lead
European studies and participate in larger global clinical studies for psoriasis indication subject
to the terms of the Sun Pharma - Merck agreements as well as certain cost sharing agreements.
Sun Pharma will continue to lead development of tildrakizumab for other indications where
Almirall will have right of first negotiation for certain indications in Europe.On 6 September
2016 Sun Pharma announced that it has signed a strategic distribution alliance with Mitsubishi
Tanabe Pharma Corporation Japan for 14 prescription brands.
Under this alliance Mitsubishi Tanabe Pharma Corporation will market and distribute all the 14
brands as well as provide information on their proper use to healthcare professionals.On 19
October 2016 Sun Pharma and International Centre for Genetic Engineering and Biotechnology
(ICGEB) announced their new collaboration for development of a dengue vaccine targeted
against all the four serotypes of Dengue virus that cause disease in humans. According to the
agreement Sun Pharma will fund and support further development of the vaccine candidate and
existing ICGEB Know-How and Patents. ICGEB will grant Sun Pharma exclusive rights and
licenses for development and commercialization of this vaccine globally. ICGEB will receive
pre-defined royalty and milestone payments.
On 26 October 2016 Sun Pharmaceutical Industries announced the execution of definitive
agreements by its wholly owned subsidiary for the acquisition of 100% of Ocular Technologies
Sarl (OTS) a portfolio company of Auven Therapeutics (Auven) an international private equity
company focused on accelerated development of breakthrough therapeutic drugs.
OTS owns exclusive worldwide rights to Seciera (cyclosporine A 0.09% ophthalmic solution).
Sun Pharma will pay Auven US$ 40 million upfront plus contingent development milestones and
sales milestones as well as tiered royalty on sales of Seciera as consideration for this
acquisition.On 23 November 2016 Sun Pharma announced the execution of definitive
agreements by its wholly owned subsidiary for the acquisition of 85.1% ofJSC Biosintez a
Russian pharmaceutical company engaged in manufacture and marketing of pharmaceutical
products in Russia and CIS region. The equity consideration for the 85.1% stake is US$ 24
12. million. Sun Pharma would also assume a debt of approximately US$ 36 million as part of this
transaction. Biosintez is a Russian pharmaceutical company focusing on the hospital segment
with annual revenues of approximately US$ 52 million for 2015. It has a manufacturing facility
in Penza region with capabilities to manufacture a wide variety of dosage forms including
pharmaceuticals for injections blood substitutes blood preservatives ampoules tablets ointment
creams gels suppositories APIs etc.
On 28 November 2016 Sun Pharma announced the launch of a branded ophthalmic product
BromSite 0.075% in the US market. It was the first branded product launched by the company in
the USA following its focus on Specialty Business. On 12 December 2016 Sun Pharma and
Israel-based Moebius Medical announced that they have entered into an exclusive worldwide
licensing deal to further develop MM-II a novel pharmaceutical candidate for the treatment of
pain in osteoarthritis. According to the agreement Sun Pharma will fund further development of
Moebius Medical's lead product MM-II and undertake its global commercialization. Moebius
Medical will conduct requisite pre-clinical studies and will assume responsibility for product
development and manufacturing through the end of Phase-II studies. Sun Pharma will assume
responsibility for further clinical studies regulatory submissions and product commercialization.
Moebius Medical will receive an upfront payment development-based and sales-based milestone
payments and tiered royalties on sales from Sun Pharma.
On 22 December 2016 Sun Pharma announced its plans to acquire a branded oncology product
Odomzo from Novartis. The agreement was signed for an upfront payment of US$ 175 million
and additional milestone payments. Odomzo (Sonidegib) was approved by the USFDA in July
2015. Odomzo is a hedgehog pathway inhibitor indicated for the treatment of adult patients with
locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation
therapy or those who are not candidates for surgery or radiation therapy.
On 4 January 2017 Sun Pharma announced successful Phase 3 confirmatory clinical trial results
for Seciera for the treatment of dry eye disease. Seciera is being developed by Ocular
Technologies a company acquired by Sun Pharma. Following this acquisition Sun Pharma owns
13. exclusive worldwide rights to Seciera and is developing it to commercialize for global markets
including US Europe and Japan as well as several emerging markets.
On 14 March 2017 Sun Pharmaceutical Industries announced that USFDA will lift the Import
Alert imposed on the company's Mohali Punjab manufacturing facility and remove the facility
from the Official Action Initiated (OAI) status. This proposed action will clear the path for Sun
Pharma to supply approved products from the Mohali facility to the US market subject to normal
USFDA regulatory requirements. The Mohali facility was inherited by Sun Pharma as part of its
acquisition of Ranbaxy Laboratories in 2015. The USFDA had taken action against the Mohali
facility in 2013 when it ordered the facility to be fully subject to Ranbaxy's Consent Decree of
Permanent Injunction. Certain conditions of the consent decree will continue to be applicable to
the Mohali facility.
On 27 June 2017 Sun Pharmaceutical Industries and National Institute of Virology (NIV) Pune
an institution of the Indian Council of Medical Research Department of Health Research
Ministry of Health and Family Welfare New Delhi announced that they have signed an
agreement for testing phytopharmaceutical biologic and chemical entities developed by Sun
Pharma against Zika Chikungunya and Dengue viruses. Sun Pharma will provide drug molecules
to NIV for testing against Zika Chikungunya and Dengue in model systems. Candidate
molecules with encouraging data will then be taken forward for commercial development.
On 4 July 2017 Sun Pharmaceutical Industries and Samsung BioLogics announced a strategic
long-term manufacturing agreement for Tildrakizumab an investigational IL-23p19 inhibitor
being evaluated for the treatment of moderate to severe plaque psoriasis. According to the
agreement Sun Pharma has appointed Samsung BioLogics to manufacture Tildrakizumab. The
approximate value of the contract will be US$ 55.5 million. The regulatory filings associated
with tildrakizumab have been accepted for review by the U.S. Food and Drug Administration
and the European Medicines Agency (EMA).
On 16 January 2018 Sun Pharmaceutical Industries announced that its wholly owned subsidiaries
have reached an agreement with Ironwood Pharmaceuticals Inc. and Allergan plc to resolve the
14. patent litigation regarding submission of an Abbreviated New Drug Application (ANDA) for a
generic version of Linzess (Linaclotide capsules) in the US. Pursuant to the terms of the
settlement Ironwood Pharmaceuticals and Allergan will grant the wholly owned subsidiaries of
Sun Pharma a license to market a generic version of Linzess in the United States beginning 1
February 2031 (subject to USFDA approval) or earlier under certain circumstances.
15. ACQUISIONS AND JOINT VENTURES
Sun Pharma has complemented growth with select acquisitions over the last two decades. In
1996, Sun purchased a bulk drug manufacturing plant at Ahmednagar from Knoll
Pharmaceuticals and MJ Pharma's dosage plant at Halol that are both U.S. FDA approved today.
In 1997, Sun acquired Tamil Nadu Dadha Pharmaceuticals Limited (TDPL) based in Chennai,
mainly for their extensive gynaecology and oncology brands. Also in 1997, Sun Pharma initiated
their first foray into the lucrative US market with the acquisition of Caraco Pharmaceuticals,
based in Detroit.
In 1998, Sun acquired a number of respiratory brands from Natco Pharma. Other notable
acquisitions include Milmet Labs and Gujarat Lyka Organics (1999), Pradeep Drug Company
(2000), Phlox Pharma (2004), a formulation plant at Bryan, Ohio and ICN, Hungary from
Valeant Pharma and Able Labs (2005), and Chattem Chemicals (2008). In 2010, the company
acquired a large stake in Taro Pharmaceuticals, amongst the largest generic derma companies in
the US, with operations across Canada and Israel. The company currently owns ~ 69% stake in
Taro, for about $260 million.
In 2011, Sun Pharma entered into a joint venture with MSD to bring complex or differentiated
generics to emerging markets (other than India).
In 2012, Sun announced acquisitions of two US companies: DUSA Pharmaceuticals. a
dermatology device company; and generic pharma company URL Pharma. In 2013, the company
announced an R&D joint venture for ophthalmology with the research company, Intrexon.
On 6 April 2014, Sun Pharma announced that it would acquire 100% of Ranbaxy Laboratories
Ltd, in an all-stock transaction, valued at $4 billion. Japan's Daiichi Sankyo held 63.4% stake in
Ranbaxy. After this acquisition, Sun Pharma has become the largest pharmaceutical company in
India, the largest Indian Pharma company in the US, and the 5th largest generic company
worldwide.
In December 2014, the Competition Commission of India approved Sun Pharma's $3.2 billion
bid to buy Ranbaxy Laboratories, but ordered the firms to divest seven products to ensure the
deal doesn't harm competition.
16. In March 2015, Sun Pharma announced it had agreed to buy GlaxoSmithKline's opiates business
in Australia to strengthen its pain management portfolio.